NextCure, Inc. (NXTC) insider trading.
In Q3 2026, insiders at NextCure, Inc. reported 14 non-derivative transactions on 4 Forms 3, 4 and 5: 13 open-market purchases worth $1.7M and 1 sale worth $185K.
- Transactions
- 14
- Purchases (P)
- 13
- Sales (S)
- 1
- Net shares, P minus S
- 316,761
- Insiders
- 2
- Last filed
- 2026-08-12
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC / Schneeberger Daniel | TenPercentOwner | 13 | 13 | 0 |
| Simcere Zaiming, Inc. / Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. / Ren Jinsheng / Simcere Pharmaceutical Group Ltd / Tang Renhong / Simcere Zaiming Pharmaceutical Co., Ltd. | Other | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-10 | Simcere Zaiming, Inc. / Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. / Ren Jinsheng / Simcere Pharmaceutical Group Ltd / Tang Renhong / Simcere Zaiming Pharmaceutical Co., Ltd. | S (D) | 30,000 | $6.16 | 308,636 | Form 4 |
| 2026-07-31 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 8,003 | $4.8 | 722,419 | Form 4 |
| 2026-07-31 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 3,300 | $4.98 | 689,416 | Form 4 |
| 2026-07-31 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 25,000 | $4.98 | 714,416 | Form 4 |
| 2026-07-30 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 50,000 | $4.97 | 443,266 | Form 4 |
| 2026-07-30 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 20,000 | $5 | 463,266 | Form 4 |
| 2026-07-30 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 20,000 | $5 | 483,266 | Form 4 |
| 2026-07-30 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 25,000 | $4.81 | 508,266 | Form 4 |
| 2026-07-30 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 77,850 | $4.96 | 686,116 | Form 4 |
| 2026-07-30 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 100,000 | $4.9 | 608,266 | Form 4 |
| 2026-07-29 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 1,810 | $5 | 391,666 | Form 4 |
| 2026-07-29 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 1,600 | $5 | 393,266 | Form 4 |
| 2026-07-28 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 6,400 | $4.95 | 389,856 | Form 4 |
| 2026-07-27 | ADAR1 Capital Management, LLC / Schneeberger Daniel | P (A) | 7,798 | $5 | 383,456 | Form 4 |
Transaction codes in this quarter
Get NXTC insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1661059&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · NXTC company page · NextCure, Inc. on SEC.gov
Questions
Are insiders buying or selling NextCure, Inc. (NXTC)?
In Q3 2026, insiders at NextCure, Inc. reported 14 non-derivative transactions on 4 Forms 3, 4 and 5: 13 open-market purchases worth $1.7M and 1 sale worth $185K. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these NextCure, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/nxtc.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.